International Ophthalmology

, Volume 38, Issue 1, pp 11–18 | Cite as

Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore

  • Leslie Ang
  • Aera Kee
  • Tun Hang Yeo
  • V. G. Dinesh
  • Su Ling Ho
  • Stephen C. Teoh
  • Rupesh Agrawal
Original Paper



To report the clinical features and outcome of patients with presumed tubercular uveitis (TBU).


Retrospective analysis of patients with presumed TBU at a tertiary referral eye care centre in Singapore between 2007 and 2012 was done. Main outcome measures were failure of complete resolution of uveitis or recurrence of inflammation.


Fifty three patients with mean age of 44.18 ± 15.26 years with 54.72% being males were included. 19 (35.85%) had bilateral involvement, with panuveitis and anterior uveitis being the most common presentations. 36 (67.92%) patients received antitubercular therapy (ATT), and 28 received concurrent systemic steroids. 15 (28.30%) eyes of 11 (30.55%) patients in the ATT group and 4 (21.05%) eyes of 3 (17.64%) patients in the non-ATT group had treatment failure (p value = 0.51).


The use of ATT, with or without concurrent corticosteroid, may not have a statistically significant impact in improving treatment success in patients with presumed TBU.


Antitubercular therapy Panuveitis Tubercular uveitis Steroids Tuberculosis 


Author’s contributions

LA was involved in the conceptualization of the study, data acquisition, analysis of data, and drafting and writing up of the manuscript. AK, YTH, and VGD were involved in the acquisition and analysis of the data. HSL, ST, and RA were involved in conceptualization of the study, writing up and editing of the manuscript.

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

Supplementary material

10792_2016_401_MOESM1_ESM.xlsx (48 kb)
Supplementary material 1 (XLSX 48 kb)


  1. 1.
    World Health Organization (2014) In: ©1948 Tuberculosis fact sheet. WHO global TB programme, GenevaGoogle Scholar
  2. 2.
    World Health Organization (2010) Global tuberculosis control: key findings from the December 2009 WHO report. Wkly Epidemiol Rec 85:69–80Google Scholar
  3. 3.
    Gupta V, Gupta A, Rao NA (2007) Intraocular tuberculosis—an update. Surv Ophthalmol 52(6):561–587CrossRefPubMedGoogle Scholar
  4. 4.
    Bouza E, Merino P, Munoz P et al (1997) Ocular tuberculosis. A prospective studying a general hospital. Medicine 76(1):53–61CrossRefPubMedGoogle Scholar
  5. 5.
    Rao NA, Saraswathy S, Smith RE (2006) Tuberculous uveitis: distribution of Mycobacterium Tuberculosis in the retinal pigment epithelium. Arch Ophthalmol 124(12):1777–1779CrossRefPubMedGoogle Scholar
  6. 6.
    Morimura Y, Okada AA, Kawahara S et al (2002) Tuberculin skin testing in uveitis patients and treatment of presumed intraocular tuberculosis in Japan. Ophthalmology 109(5):851–857CrossRefPubMedGoogle Scholar
  7. 7.
    Helm CJ, Holland GM (1993) Ocular tuberculosis: major review. Surv Ophthalmol 38(3):229–256CrossRefPubMedGoogle Scholar
  8. 8.
    Sheu SJ, Shyu JS, Chen LM et al (2001) Ocular manifestations of tuberculosis. Ophthalmology 108(9):1580–1585CrossRefPubMedGoogle Scholar
  9. 9.
    Demirci H, Shields CL, Shields JA et al (2004) Ocular tuberculosis masquerading as ocular tumors. Surv Ophthalmol 49(1):78–89CrossRefPubMedGoogle Scholar
  10. 10.
    Varma D, Anand S, Reddy AR et al (2006) Tuberculosis: an under-diagnosed aetiological agent in uveitis with an effective treatment. Eye 20(9):1068–1073CrossRefPubMedGoogle Scholar
  11. 11.
    Sanghvi C, Bell C, Woodhead M et al (2011) Presumed tuberculous uveitis: diagnosis, management and outcome. Eye 25(4):475–480CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bansal R, Gupta A, Gupta V et al (2008) Role of anti-tubercular therapy in uveitis with latent/manifest tuberculosis. Am J Ophthalmol 146(5):772–779CrossRefPubMedGoogle Scholar
  13. 13.
    Ang M, Hedayatfar A, Wong W et al (2012) Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case-control study. Br J Ophthalmol 96(3):332–336CrossRefPubMedGoogle Scholar
  14. 14.
    Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516CrossRefPubMedGoogle Scholar
  15. 15.
    Manousaridis K, Ong E, Stenton C et al (2013) Clinical presentation, treatment, and outcomes in presumed intraocular tuberculosis: experience from Newcastle upon Tyne, UK. Eye 27(4):480–486CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Patel SS, Saraiya NV, Tessler HH et al (2013) Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity. JAMA Ophthalmol 131(6):752–758CrossRefPubMedGoogle Scholar
  17. 17.
    Gupta A, Bansal R, Gupta V et al (2010) Ocular signs predictive of tubercular uveitis. Am J Ophthalmol 149(4):562–570CrossRefPubMedGoogle Scholar
  18. 18.
    Dinnes J, Deeks J, Kunst H et al (2007) A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 11(3):1–196CrossRefPubMedGoogle Scholar
  19. 19.
    Vasconcelos-Santos DV, Zierhut M, Rao NA (2009) Strengths and weaknesses of diagnostic tools for tuberculous uveitis. Ocul Immunol Inflamm 17(5):351–355CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Albini TA, Karakousis PC, Rao NA (2008) Interferon-gamma release assays in the diagnosis of tuberculosis uveitis. Am J Ophthalmol 146(4):486–488CrossRefPubMedGoogle Scholar
  21. 21.
    Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149(3):177–184CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kurup SK, Buggage RR, Clarke GL et al (2006) Gamma interferon assay as an alternative to PPD skin testing in selected patients with granulomatous intraocular inflammatory disease. Can J Ophthalmol 41(6):737–740CrossRefPubMedGoogle Scholar
  23. 23.
    Olson NA, Davidow AL, Winston CA et al (2012) A national study of socioeconomic status and tuberculosis rates by country of birth, United States, 1996–2005. BMC Public Health 12:365CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cantwell MF, McKenna MT, McCray E et al (1998) Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 157(4 Pt 1):1016–1020CrossRefPubMedGoogle Scholar
  25. 25.
    Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3(10 Suppl 2):S231–S279PubMedGoogle Scholar
  26. 26.
    Laserson K, Thorpe LE, Leimane V et al (2005) Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9(6):640–645PubMedGoogle Scholar
  27. 27.
    Rosen PH, Spalton DJ, Graham EM (1990) Intraocular tuberculosis. Eye (Lond) 4(3):486–492CrossRefGoogle Scholar
  28. 28.
    Psilas K, Aspiotis M, Petroutsos G et al (1991) Antituberculosis therapy in the treatment of peripheral uveitis. Ann Ophthalmol 23(7):254–258PubMedGoogle Scholar
  29. 29.
    Basu S, Nayak S, Padhi TR et al (2013) Progressive ocular inflammation following anti-tubercular therapy for presumed ocular tuberculosis in a high-endemic setting. Eye 27(5):657–662CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    World Health Organization (2010) Treatment of tuberculosis guidelines 4th edn. World Health Organization, GenevaGoogle Scholar
  31. 31.
    Winston CA, Mitruka K (2012) Treatment duration for patients with drug-resistant tuberculosis, United States. Emerg Infect Dis 18(7):1201–1202CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Sharma SK, Kumar S, Saha PK et al (2011) Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients. Indian J Med Res 133:312–315PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Leslie Ang
    • 1
  • Aera Kee
    • 2
  • Tun Hang Yeo
    • 1
  • V. G. Dinesh
    • 3
  • Su Ling Ho
    • 1
  • Stephen C. Teoh
    • 1
    • 4
  • Rupesh Agrawal
    • 1
  1. 1.National Healthcare Group Eye InstituteTan Tock Seng HospitalSingaporeSingapore
  2. 2.Yong Loo Lin School of MedicineNational University of SingaporeSingaporeSingapore
  3. 3.Department of General MedicineTan Tock Seng HospitalSingaporeSingapore
  4. 4.Eagle Eye CentreSingaporeSingapore

Personalised recommendations